KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Current Liabilities (2016 - 2025)

Nektar Therapeutics has reported Total Current Liabilities over the past 16 years, most recently at $53.5 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $53.5 million for Q4 2025, down 12.81% from a year ago — trailing twelve months through Dec 2025 was $53.5 million (down 12.81% YoY), and the annual figure for FY2025 was $53.5 million, down 12.81%.
  • Total Current Liabilities for Q4 2025 was $53.5 million at Nektar Therapeutics, down from $66.3 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for NKTR hit a ceiling of $140.0 million in Q3 2021 and a floor of $50.7 million in Q2 2023.
  • Median Total Current Liabilities over the past 5 years was $67.9 million (2022), compared with a mean of $77.9 million.
  • Biggest five-year swings in Total Current Liabilities: tumbled 67.25% in 2021 and later soared 35.35% in 2025.
  • Nektar Therapeutics' Total Current Liabilities stood at $85.2 million in 2021, then fell by 19.95% to $68.2 million in 2022, then fell by 24.83% to $51.3 million in 2023, then rose by 19.76% to $61.4 million in 2024, then decreased by 12.81% to $53.5 million in 2025.
  • The last three reported values for Total Current Liabilities were $53.5 million (Q4 2025), $66.3 million (Q3 2025), and $71.4 million (Q2 2025) per Business Quant data.